Minimizing Risk of Cancer Therapeutics

Phys Med Rehabil Clin N Am. 2018 Nov;29(4):701-719. doi: 10.1016/j.pmr.2018.06.006. Epub 2018 Sep 5.

Abstract

Cancer treatments continue to advance the management and survival of patients. However, use of these regimens can lead to significant side effects both temporary and permanent. Neuromuscular side effects include chemotherapy-induced peripheral neuropathy and radiation fibrosis syndrome. At this time, the only way to resolve the neurotoxicity is reduction or discontinuation of the offending agent. In an attempt to limit interference with a patient's chemotherapy regimen and mitigate chronic disability, efforts for early detection through subjective clinical evaluations and objective measurement with electrodiagnostics can help to improve symptom management and minimize alteration in treatment.

Keywords: Chemotherapy-induced peripheral neuropathy; Platinum-based toxicity; Radiation fibrosis; Radiation fibrosis syndrome; Taxane-based toxicity.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Electrodiagnosis
  • Humans
  • Neoplasms / therapy*
  • Neurotoxicity Syndromes / diagnosis
  • Neurotoxicity Syndromes / etiology
  • Neurotoxicity Syndromes / prevention & control*
  • Peripheral Nervous System Diseases / diagnosis
  • Peripheral Nervous System Diseases / etiology
  • Peripheral Nervous System Diseases / prevention & control*
  • Radiation Injuries / diagnosis
  • Radiation Injuries / etiology
  • Radiation Injuries / prevention & control*
  • Risk

Substances

  • Antineoplastic Agents